Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 19M | 5M | 40K | 0 | 365K |
| Gross Profit | 9M | 3M | -95K | 0 | 105K |
| Operating Income | -4M | -12M | -5M | -4M | -7M |
| EBITDA | -4M | -4M | -5M | -2M | -4M |
| Net Income | -21M | -9M | -6M | -3M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.04
+1.25% today
1Y Change
-68.73%
Window
Jun 20, 2025 → Jun 16, 2026
Coverage: 248 bars · Jun 20, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
QT Imaging Holdings, Inc. (QTI) is a Healthcare stock with a market cap of $180.00M and listed on NASDAQ. The stock last traded around $4.04 and down 68.7% across the available one-year price window (Jun 20, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +287.9%, EPS growth of -183.1%, a dividend yield of 0.0%. What stands out right now is revenue +287.9%, EPS -183.1%, free cash flow +99.9% with operating margin -23.4% and ROIC -28.4%. Valuation already assumes a fairly strong business story at price/sales 9.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines QTI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QTI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
QTI Max Drawdown
-90.57%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for QTI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$365.1K
FY Net Income
-$5.4M
-95.2% YoY
Free Cash Flow
-$2.7M
+30.0% YoY
Revenue Growth
+287.9%
EPS Growth
-183.1%
Gross Margin
45.4%
Net Margin
-111.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 19M | 5M | 40K | 0 | 365K |
| Gross Profit | 9M | 3M | -95K | 0 | 105K |
| Operating Income | -4M | -12M | -5M | -4M | -7M |
| EBITDA | -4M | -4M | -5M | -2M | -4M |
| Net Income | -21M | -9M | -6M | -3M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10M | 1M | 2K | 455K | 2M |
| Total Assets | 23M | 6M | 23M | 8M | 8M |
| Total Liabilities | 17M | 16M | 13M | 9M | 6M |
| Shareholder Equity | 6M | -10M | 11M | -2M | 3M |
| Total Debt | 5M | 10M | 3M | 8M | 4M |
| Net Debt | -5M | 9M | 3M | 7M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+30.1% YoY
Capital Expenditures
20K
+13.7% YoY
Free Cash Flow
3M
+30.0% YoY
Key ratios
Gross Margin
45.4%
Operating Margin
-23.4%
Net Margin
-111.4%
ROE
364.1%
Debt / Equity
0.81x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.